NASDAQ NMS - GLOBAL MARKET · LBRX
-2.34% · -$0.7900 · Vol 186.6K
Market closed · last close 4:00 PM ET · price as of 16:01:12 ET
LB Pharmaceuticals Inc

LB Pharmaceuticals Inc

Pharmaceuticals
$32.95

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is LBRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for LBRX are being assembled.
About LB Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2025
Employees
27
Country
US

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$33.74
Day high
$34.20
Day low
$31.97
Previous close
$33.74
52W high
$34.20
-3.67% from high
52W low
$31.97
44% of range
Market cap
$967.6M
P/E
13.36×
EPS
$2.47
Shares out
28.7M
Volume
186.6K
VWAP
$32.64
Price history computed in-house
SMA 50 $32.95 · above
SMA 200 $32.95 · above
52W position 44%
Veridion warehouse edge

Warehouse intelligence for LBRX.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

LBRX insider activity

LB Pharmaceuticals Inc

Score
Coverage building
Pressure
Net buying
Filings
8
Buys / sells
8 / 0
Net value
$85.0M
Insiders
4
Named filers
KD
KROIN DAVID
Insider
Leadership
PL
Pontifax Management 4 G.P. (2015) Ltd.
Insider
Leadership
NR
Nussbaum Ran
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net buying: $85.0M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-02-102026-02-06KROIN DAVIDInsiderbuy$21.1793,92593,925$2.0MSEC Form 4
2026-02-102026-02-06KROIN DAVIDInsiderbuy$21.17378,444378,444$8.0MSEC Form 4
2025-09-162025-09-12Pontifax Management 4 G.P. (2015) Ltd.Insiderbuy$15.001,000,0001,411,681$15.0MSEC Form 4
2025-09-162025-09-12Nussbaum RanInsiderbuy$15.001,000,0001,411,681$15.0MSEC Form 4
2025-09-162025-09-12KROIN DAVIDInsiderbuy$15.00666,666666,666$10.0MSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 3 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

LBRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LBRX in this window.
Lobbying spend

LBRX lobbying filings, year to date.

Registered lobbying filings matched to LB Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LBRX in this window.
Latest news · LBRX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for LBRX.
Options
Sovereign unlock shows live options positioning for LBRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.